Status:
RECRUITING
Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Conditions:
Acute Graft-versus-Host Disease
Eligibility:
All Genders
16+ years
Phase:
PHASE2
Brief Summary
To assess the efficacy and safety of using recombinant humanized anti-CD25 monoclonal antibody injection as a prophylactic strategy for reducing the incidence of severe acute graft-versus-host disease...
Eligibility Criteria
Inclusion
- Age ≥ 16 years, regardless of gender.
- Patients with hematologic disorders who are scheduled to receive allo-HSCT.
- Voluntarily join this study, sign the informed consent form, have good compliance, and be willing to cooperate with follow-up.
Exclusion
- Patients who have received a second or multiple transplants.
- Patients who are allergic to, or intolerant of, a recombinant humanized anti-CD25 monoclonal antibody injection.
- Pregnant or lactating female patients or female patients who are unable to take effective contraceptive measures during the entire trial period.
Key Trial Info
Start Date :
March 3 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
174 Patients enrolled
Trial Details
Trial ID
NCT06880419
Start Date
March 3 2025
End Date
December 31 2026
Last Update
August 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China, 300020